Bristol-Myers Drops Hepatitis C Drug After Patient Death

Bristol-Myers Squibb Co. has abandoned an experimental hepatitis C pill it bought for $2.5 billion earlier this year after one patient died and others were hospitalized while taking the drug in a study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.